Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Dose Optimization in Imatinib-Resistant/Intolerant CML-CP
NCT00482703Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2007
- Primary completion
- May 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Cytogenetic Response in Imatinib-Intolerant and Imatinib-Resistant Participants at 24 weeks. Started May 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00482703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482703.